{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:27:09Z","timestamp":1778729229166,"version":"3.51.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.tcm.2012.01.001","type":"journal-article","created":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T00:47:16Z","timestamp":1334018836000},"page":"6-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hemostatic Abnormalities and Relationships to Metabolic and Hormonal Status in Polycystic Ovarian Syndrome"],"prefix":"10.1016","volume":"21","author":[{"given":"Genia","family":"Burchall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Linden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Teede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrence J.","family":"Piva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcm.2012.01.001_bib1","first-page":"83","article-title":"Polycystic ovary syndrome: A major unrecognized cardiovascular risk factor in women","volume":"10","author":"Alexander","year":"2009","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.tcm.2012.01.001_bib2","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1515\/JPEM.2005.18.12.1373","article-title":"Global fibrinolytic capacity is decreased in girls with premature adrenarche: A new pathological finding?","volume":"18","author":"Andiran","year":"2005","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.tcm.2012.01.001_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0015-0282(97)00486-X","article-title":"The plasminogen activator system in women with polycystic ovary syndrome","volume":"69","author":"Atiomo","year":"1998","journal-title":"Fertil Steril"},{"key":"10.1016\/j.tcm.2012.01.001_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1046\/j.1365-2265.2000.00946.x","article-title":"Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS)","volume":"52","author":"Atiomo","year":"2000","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.tcm.2012.01.001_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/09513590009167677","article-title":"Immunohistochemical detection of plasminogen activator inhibitor-1 in polycystic ovaries","volume":"14","author":"Atiomo","year":"2000","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.tcm.2012.01.001_bib6","author":"Azziz"},{"key":"10.1016\/j.tcm.2012.01.001_bib7","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1210\/jc.2005-0628","article-title":"Health care\u2013related economic burden of the polycystic ovary syndrome during the reproductive life span","volume":"90","author":"Azziz","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tcm.2012.01.001_bib8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1210\/jc.2006-1705","article-title":"Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome","volume":"92","author":"Berneis","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tcm.2012.01.001_bib9","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1210\/jc.2003-031096","article-title":"Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease","volume":"89","author":"Boulman","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tcm.2012.01.001_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.thromres.2004.11.026","article-title":"Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome","volume":"116","author":"Carmassi","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.tcm.2012.01.001_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/humrep\/dem356","article-title":"Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome","volume":"23","author":"Cascella","year":"2008","journal-title":"Hum Reprod"},{"key":"10.1016\/j.tcm.2012.01.001_bib12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.atherosclerosis.2007.03.002","article-title":"The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels in women with the polycystic ovary syndrome","volume":"196","author":"Charitidou","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tcm.2012.01.001_bib13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00277-005-1079-4","article-title":"Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation","volume":"84","author":"Chen","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.tcm.2012.01.001_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0015-0282(16)56575-3","article-title":"Hemostatic and metabolic variables in women with polycystic ovary syndrome","volume":"61","author":"Dahlgren","year":"1994","journal-title":"Fertil Steril"},{"key":"10.1016\/j.tcm.2012.01.001_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/sj.ijo.0800435","article-title":"Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: Relationship with body fat distribution","volume":"21","author":"De Pergola","year":"1997","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.tcm.2012.01.001_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2265.2007.02849.x","article-title":"Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome","volume":"67","author":"Demirel","year":"2007","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.tcm.2012.01.001_bib17","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1210\/jc.2002-021391","article-title":"Platelet dysfunction in lean women with polycystic ovary syndrome and association with insulin sensitivity","volume":"88","author":"Dereli","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tcm.2012.01.001_bib18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1530\/eje.0.1500793","article-title":"The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels","volume":"150","author":"Diamanti-Kandarakis","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.tcm.2012.01.001_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2007-992118","article-title":"Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome","volume":"116","author":"Erdogan","year":"2008","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.tcm.2012.01.001_bib20","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1515\/JPEM.2008.21.10.973","article-title":"Insulin resistance, obesity, hypofibrinolysis, hyperandrogenism, and coronary heart disease risk factors in 25 pre-perimenarchal girls age < or =14 years, 13 with precocious puberty, 23 with a first-degree relative with polycystic ovary syndrome","volume":"21","author":"Glueck","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.tcm.2012.01.001_bib21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/107602960401000404","article-title":"Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin","volume":"10","author":"Glueck","year":"2004","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.tcm.2012.01.001_bib22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/09537100600901590","article-title":"Mean platelet volume in patients with polycystic ovary disease","volume":"17","author":"Gursoy","year":"2006","journal-title":"Platelets"},{"key":"10.1016\/j.tcm.2012.01.001_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0268-9499(92)90012-7","article-title":"Effects of age, menopause and human growth-hormone on variables of fibrinolysis","volume":"6","author":"Heinrich","year":"1992","journal-title":"Fibrinolysis"},{"key":"10.1016\/j.tcm.2012.01.001_bib24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1210\/jc.2007-0842","article-title":"Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment","volume":"93","author":"Heutling","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tcm.2012.01.001_bib25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1203\/00006450-200202000-00019","article-title":"Plasminogen activator inhibitor-1 in girls with precocious pubarche: A premenarcheal marker for polycystic ovary syndrome?","volume":"51","author":"Ibanez","year":"2002","journal-title":"Pediatr Res"},{"key":"10.1016\/j.tcm.2012.01.001_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/09513590802291824","article-title":"Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome","volume":"24","author":"Karakurt","year":"2008","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.tcm.2012.01.001_bib27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00404-009-1189-7","article-title":"Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients","volume":"281","author":"Kebapcilar","year":"2010","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.tcm.2012.01.001_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00404-008-0884-0","article-title":"High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome","volume":"280","author":"Kebapcilar","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.tcm.2012.01.001_bib29","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1210\/jcem.87.7.8634","article-title":"A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome","volume":"87","author":"Kelly","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tcm.2012.01.001_bib30","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1161\/01.STR.0000231640.32543.11","article-title":"ADMA increases arterial stiffness and decreases cerebral blood flow in humans","volume":"37","author":"Kielstein","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.tcm.2012.01.001_bib31","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1080\/00016340902859315","article-title":"Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome","volume":"88","author":"Kuscu","year":"2009","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.tcm.2012.01.001_bib32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijgo.2007.09.019","article-title":"Plasminogen activator and plasma activator inhibitor-1 in young women with polycystic ovary syndrome","volume":"100","author":"Lin","year":"2008","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tcm.2012.01.001_bib33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1530\/EJE-08-0725","article-title":"Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: Influence of obesity and smoking","volume":"160","author":"Luque-Ramirez","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 5","key":"10.1016\/j.tcm.2012.01.001_bib34","first-page":"1353","article-title":"Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS)","volume":"14","author":"Macut","year":"2001","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.tcm.2012.01.001_bib35","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.tcm.2012.01.001_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cca.2007.07.006","article-title":"Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method","volume":"384","author":"Meinitzer","year":"2007","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.tcm.2012.01.001_bib37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/dc06-0618","article-title":"Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome","volume":"30","author":"Meyer","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tcm.2012.01.001_bib38","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1472-6483(10)61182-0","article-title":"Effects of lifestyle modification in polycystic ovarian syndrome","volume":"12","author":"Moran","year":"2006","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.tcm.2012.01.001_bib39","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1042\/CS20080218","article-title":"A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome","volume":"116","author":"Moran","year":"2009","journal-title":"Clin Sci (London)"},{"key":"10.1016\/j.tcm.2012.01.001_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pathophys.2006.09.006","article-title":"Acute phase proteins: C-reactive protein and fibrinogen in young women with polycystic ovary syndrome","volume":"14","author":"Nasiek","year":"2007","journal-title":"Pathophysiology"},{"key":"10.1016\/j.tcm.2012.01.001_bib42","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1016\/j.fertnstert.2008.03.039","article-title":"Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease","volume":"91","author":"Oktem","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.tcm.2012.01.001_bib43","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/09513590802549874","article-title":"Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome","volume":"25","author":"Oral","year":"2009","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.tcm.2012.01.001_bib44","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1472-6483(10)61634-3","article-title":"Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?","volume":"9","author":"Orio","year":"2004","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.tcm.2012.01.001_bib45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1076029607309176","article-title":"Elevated levels of prothrombin fragment 1 + 2 indicate high risk of thrombosis","volume":"14","author":"Ota","year":"2008","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.tcm.2012.01.001_bib46","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.atherosclerosis.2007.12.054","article-title":"Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS)","volume":"200","author":"Ozgurtas","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tcm.2012.01.001_bib47","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.fertnstert.2008.10.073","article-title":"Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters","volume":"93","author":"Pamuk","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.tcm.2012.01.001_bib48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.atherosclerosis.2008.09.010","article-title":"Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects","volume":"204","author":"Rajendran","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tcm.2012.01.001_bib49","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-2265.1996.00863.x","article-title":"Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome","volume":"45","author":"Sampson","year":"1996","journal-title":"Clin Endocrinol (Oxford)"},{"issue":"Suppl 2","key":"10.1016\/j.tcm.2012.01.001_bib50","first-page":"313","article-title":"Active platelet-derived TAFI attenuates platelet-rich thrombus lysis in vitro","volume":"7","author":"Schadinger","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tcm.2012.01.001_bib51","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1210\/jc.2007-0425","volume":"93","author":"Shaw","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tcm.2012.01.001_bib52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/gye.17.3.231.237","article-title":"Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system","volume":"17","author":"Sills","year":"2003","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.tcm.2012.01.001_bib53","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/09513590601005805","article-title":"Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity","volume":"22","author":"Slopien","year":"2006","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.tcm.2012.01.001_bib54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1741-7015-8-41","article-title":"Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan","volume":"8","author":"Teede","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.tcm.2012.01.001_bib55","doi-asserted-by":"crossref","first-page":"s65","DOI":"10.5694\/mja11.10915","article-title":"Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline","volume":"195","author":"Teede","year":"2011","journal-title":"Med J Aust"},{"key":"10.1016\/j.tcm.2012.01.001_bib56","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/humrep\/17.2.314","article-title":"Polycystic ovarian syndrome and thrombophilia","volume":"17","author":"Tsanadis","year":"2002","journal-title":"Hum Reprod"},{"key":"10.1016\/j.tcm.2012.01.001_bib57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/ncpendmet0400","article-title":"The genetics of the polycystic ovary syndrome","volume":"3","author":"Urbanek","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.tcm.2012.01.001_bib58","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0026-0495(86)90209-X","article-title":"Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects","volume":"35","author":"Vague","year":"1986","journal-title":"Metabolism"},{"key":"10.1016\/j.tcm.2012.01.001_bib59","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood.V95.9.2855.009k02_2855_2859","article-title":"Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis","volume":"95","author":"Van Tilburg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.tcm.2012.01.001_bib60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2004.12.031","article-title":"The metabolic syndrome and insulin resistance: Relationship to haemostatic and inflammatory markers in older non-diabetic men","volume":"181","author":"Wannamethee","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tcm.2012.01.001_bib61","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1210\/jc.2009-2724","article-title":"Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society","volume":"95","author":"Wild","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tcm.2012.01.001_bib62","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1210\/jcem.86.1.7103","article-title":"Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen","volume":"86","author":"Worboys","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tcm.2012.01.001_bib63","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0015-0282(01)01937-9","article-title":"Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome","volume":"76","author":"Yarali","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.tcm.2012.01.001_bib64","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/jcem.87.8.8716","article-title":"Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state","volume":"87","author":"Yildiz","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"10.1016\/j.tcm.2012.01.001_bib65","first-page":"161","article-title":"Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome","volume":"59","author":"Zwirska-Korczala","year":"2008","journal-title":"J Physiol Pharmacol"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173812000023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173812000023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:57:57Z","timestamp":1760936277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173812000023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1050173812000023"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2012.01.001","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemostatic Abnormalities and Relationships to Metabolic and Hormonal Status in Polycystic Ovarian Syndrome","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2012.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2011 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}